Get the Stockscreener App
28.58
3.48%
-1.03
Vera Therapeutics Inc stock is traded at $28.58, with a volume of 1.19M.
It is down -3.48% in the last 24 hours and down -15.19% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$29.61
Open:
$29.8
24h Volume:
1.19M
Relative Volume:
1.62
Market Cap:
$1.81B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-12.93
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
+4.08%
1M Performance:
-15.19%
6M Performance:
-28.44%
1Y Performance:
-35.85%
1-Day Range:
$28.34
$30.88
1-Week Range:
$26.86
$30.88
52-Week Range:
$25.99
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
28.58 | 1.81B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab - TipRanks
(VERA) Trading Advice - Stock Traders Daily
Vera Therapeutics Inc (VERA) may enjoy gains as insiders got busy in the recent days - Knox Daily
Evercore ISI maintains Vera Therapeutics stock with $75 target By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains Overweight on Vera Therapeutics stock By Investing.com - Investing.com Canada
Evercore ISI maintains Vera Therapeutics stock with $75 target - Investing.com
Vera Therapeutics weakness on Otsuka plans ‘makes no sense,’ says Wells Fargo - MSN
Vera Therapeutics stock drops amid rival drug update - MSN
Vera Therapeutics (NASDAQ:VERA) Hits New 1-Year LowWhat's Next? - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Vera plunges as Otsuka updates on rival therapy - MSN
Vera stock falls as Otsuka updates on IgAN drug (VERA:NASDAQ) - Seeking Alpha
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Vera Therapeutics Becomes Oversold (VERA) - Nasdaq
Vera Therapeutics stock drops amid rival drug update By Investing.com - Investing.com Australia
Vera Therapeutics stock hits 52-week low at $31.64 - MSN
Vera Therapeutics stock hits 52-week low at $31.64 By Investing.com - Investing.com Nigeria
Vera Therapeutics’ Exclusive License Agreement with Stanford University - Global Legal Chronicle
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Strategic Expansion: Vera Therapeutics Grants $5.7M in Equity Awards to Strengthen Team - StockTitan
Wolfe Research Initiates Coverage of Vera Therapeutics (VERA) with Outperform Recommendation - MSN
Vera Therapeutics (NASDAQ:VERA) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Now Covered by Analysts at Wolfe Research - Armenian Reporter
Vera Therapeutics Inc (VERA) Stock: Assessing the Risk and Reward - The News Heater
Wolfe Research Begins Coverage on Vera Therapeutics (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Upgraded at Wolfe Research - Defense World
Vera Therapeutics initiated with an Outperform at Wolfe Research - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research Initiates Coverage on Vera Therapeutics With Outperform Rating, $49 Price Target - Marketscreener.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 4.9%Here's Why - MarketBeat
SG Americas Securities LLC Has $857,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
The Goldman Sachs Group Begins Coverage on Vera Therapeutics (NASDAQ:VERA) - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
The Goldman Sachs Group Initiates Coverage on Vera Therapeutics (NASDAQ:VERA) - Defense World
SG Americas Securities LLC Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Goldman Sachs Initiates Vera Therapeutics at Buy With $58 Price Target -January 28, 2025 at 07:43 am EST - Marketscreener.com
Polycythemia Vera Pipeline 2024: Clinical Trials Overview, - openPR
Research Analysts Set Expectations for VERA FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts VERA FY2025 Earnings - MarketBeat
Top 3 Health Care Stocks That Could Blast Off This Quarter - Benzinga
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Analysts - Defense World
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Jan 08 '25 |
Sale |
41.74 |
17,500 |
730,535 |
143,603 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):